NCT04659096View on ClinicalTrials.gov

A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

ION537

ION537 will be administered by IV injection.

Trial Locations (1)

77030

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY